Loss of circadian rhythmicity fundamentally affects the neuroendocrine, immune, and autonomic system, similar to chronic stress and may play a central role in the development of stress-related disorders. Recent articles have focused on the role of sleep and circadian disruption in the pathophysiology of posttraumatic stress disorder (PTSD), suggesting that chronodisruption plays a causal role in PTSD development. Direct and indirect human and animal PTSD research suggests circadian system-linked neuroendocrine, immune, metabolic and autonomic dysregulation, linking circadian misalignment to PTSD pathophysiology. Recent experimental findings also support a specific role of the fundamental synchronizing pineal hormone melatonin in mechanisms of sleep, cognition and memory, metabolism, pain, neuroimmunomodulation, stress endocrinology and physiology, circadian gene expression, oxidative stress and epigenetics, all processes affected in PTSD. In the current paper, we review available literature underpinning a potentially beneficiary role of an add-on melatonergic treatment in PTSD pathophysiology and PTSD-related symptoms. The literature is presented as a narrative review, providing an overview on the most important and clinically relevant publications. We conclude that adjuvant melatonergic treatment could provide a potentially promising treatment strategy in the management of PTSD and especially PTSD-related syndromes and comorbidities. Rigorous preclinical and clinical studies are needed to validate this hypothesis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jpi.12330 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmacologic prophylaxis of postoperative delirium in elderly patients: A network meta-analysis of randomized controlled trials.
J Psychiatr Res
November 2024
Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK; Mind-Body Interface Research Center (MBI-Lab), China Medical University Hospital, Taichung, Taiwan; College of Medicine, China Medical University, Taichung, Taiwan; An-Nan Hospital, China Medical University, Tainan, Taiwan. Electronic address:
Article Synopsis
- The study addresses the high rates of postoperative delirium (POD) in elderly patients and seeks to evaluate the effectiveness of various pharmacological interventions to prevent it.
- A network meta-analysis was performed on 44 randomized controlled trials (RCTs) with 11,178 patients, focusing on the incidence of POD and tolerability of treatments.
- Results showed that atypical antipsychotics were the most effective in reducing delirium, while no significant differences were found in dropout rates or all-cause mortality among the treatment groups compared to placebo.
Novel applications of sleep pharmacology as delirium therapeutics.
Sleep Med Rev
October 2024
University of Rochester Medical Center, Rochester, NY, USA.
Sleep-wake and circadian disruption (SCD) is a core feature of delirium. It has been hypothesized that SCD contributes to delirium pathogenesis; therefore, interventions that prevent or reverse SCD represent an array of promising opportunities in relation to delirium. This review explores the relationship between sleep-wake/circadian physiology and delirium pathophysiology with a focus on neurotransmitter systems.
View Article and Find Full Text PDFEffects of Approved Pharmacological Interventions for Insomnia on Mood Disorders: A Systematic Review.
Clin Neuropsychiatry
October 2024
Department of Surgical, Medical and Molecular Pathology, Critical and Care Medicine, University of Pisa, Pisa, Italy, Department of Neuroscience, Azienda Ospedaliera Universitaria Pisana (AUOP), Pisa, Italy.
Objective: Insomnia can be a contributing factor, a comorbid disorder, or a transdiagnostic element to several mental disorders, including mood disorders (MDs). A recent meta-analysis has already shown the effectiveness of cognitive behavioral treatment (CBT) for insomnia that is comorbid with MDs. This work aimed to systematically review data on pharmacological insomnia treatment in the context of MDS.
View Article and Find Full Text PDF[Melatonergic antidepressant agomelatine: augmentation of antipsychotic drugs in treatment of post-schizophrenic depression].
Zh Nevrol Psikhiatr Im S S Korsakova
September 2024
Mental Health Research Center, Moscow, Russia.
Article Synopsis
- - The article reviews the effectiveness of agomelatine used alongside antipsychotics for treating post-schizophrenic depression (PSD), based on data from 5 studies involving 137 patients over therapy durations of 28 to 180 days.
- - Results indicated a significant improvement in patient symptoms and remission rates, alongside a good safety and tolerability profile for agomelatine.
- - However, the review highlights methodological limitations, such as small sample sizes and lack of controlled trials, suggesting the need for more rigorous studies to validate these findings.
Melatonergic Signaling Sustains Food Allergy Through FcεRI Recycling.
Research (Wash D C)
July 2024
State Key Laboratory of Livestock and Poultry Breeding, Guangdong Laboratory of Lingnan Modern Agriculture, College of Animal Science, South China Agricultural University, Guangzhou, China.
The prevalence of food allergies is increasing dramatically and causing serious public health concerns. Notably, melatonin metabolism imbalance in patients with food allergies; however, the role of melatonin in food allergies remains unclear. Here, we demonstrated that melatonin suppresses food allergy responses and reprograms the gut microbiota of food-allergic mice, while melatonin aggravates food allergy during gut microbiota depletion.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!